Cryoservice manager runs the extra mile for Cancer Research

David Bryant completes 145-mile Grand Union Canal Run from Birmingham to London

The 145-mile Grand Union Canal Run is generally acknowledged as Britain’s longest continual race. Starting in Broad Street, Birmingham and finishing in Little Italy, London, competitors have to complete the race in 45 hours.

David Bryant, Cryoservice's business manager for science and industry, took 39 hours 15 minutes to complete the distance, running without sleep or a reasonable break.

‘The race is extremely challenging with only 40% of the starting line up normally finishing, so a hard training regime was required even to be in with a chance of reaching London,’ he said.

‘What kept me going was the knowledge that so many people had sponsored me and that the money raised would be going to a good cause.’

Bryant raised £3,350 for Cancer Research and came 16th.

Cryoservice, a supplier of specialist gases for science, leisure and industry, based in Worcester, UK, is a long-term business partner of Cancer Research UK and was recently short-listed for Supplier of the Year award, in recognition of its commitment and support of the organisation.

You may also like

Regulatory

Standard proposed to clarify endotoxin testing for single-use systems

The guide will address variability when assessing bacterial endotoxins on large-scale pharmaceutical equipment
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Personal Protection

Almost 60% of workplace injuries from harmful substances are burns

Chemical burns continue to be the leading type of non-fatal injury caused by exposure to or contact with harmful substances in workplaces across Great Britain
Regulatory

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma announces that the US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440
Finance

Evestia Clinical to merge with Atlantic Research Group

The merger delivers on Evestia Clinical’s strategy of targeted growth through the expansion of services, enhanced technology and broadened geographical reach
Manufacturing

Molecular Devices unveils next-generation SpectraMax Multi-Mode Microplate Readers

Honouring a legacy of product line reliability and strength, the SpectraMax Multi-Mode Microplate Readers have been transformed with next-generation innovation to improve research capabilities and provide unparalleled flexibility for a wide range of assays and applications
Subscribe now